Instrument Inactif

Communiqués Spectranetics Corp

Actions

US84760C1071

Equipement et technologie médicale avancés

Communiqués

10/08/17	Spectranetics Announces Fundamental Change, Make-Whole Adjustment Event, Share Exchange Event and Supplemental Indenture for 2.625% Convertible Senior Notes due 2034	GL
03/08/17	Spectranetics Reports Second Quarter 2017 Revenue of $74.7 million	GL
26/07/17	Spectranetics Announces FDA Approval of Stellarex™ Drug-Coated Balloon	GL
13/07/17	Spectranetics Announces Second Quarter Earnings Release Date	GL
06/07/17	Brower Piven Commences an Investigation into the Proposed Sale of The Spectranetics Corporation and Encourages Shareholders to Contact the Firm for Additional Information	BU
30/06/17	Levi & Korsinsky, LLP Reminds Investors of an Investigation Into Whether the Sale of The Spectranetics Corporation to Royal Philips for $38.50 Per Share is Fair to Shareholders	BU
29/06/17	Brower Piven Commences an Investigation into the Proposed Sale of The Spectranetics Corporation and Encourages Investors to Contact the Firm for Additional Information	BU
28/06/17	THE SPECTRANETICS CORPORATION Rigrodsky & Long, P.A. Announces Investigation of Buyout	BU
28/06/17	Levi & Korsinsky, LLP Announces an Investigation Into Whether the Sale of The Spectranetics Corporation to Royal Philips for $38.50 Per Share is Fair to Shareholders	BU
28/06/17	Philips to acquire The Spectranetics Corporation to accelerate expansion in image-guided therapy devices to treat cardiac and peripheral vascular disease	GL
14/06/17	Spectranetics Announces Election of New Chairperson of the Board of Directors	GL
09/06/17	Spectranetics Announces $140 Million Debt Refinancing	GL
27/04/17	Spectranetics Reports First Quarter 2017 Revenue of $69.7 million	GL
07/04/17	Spectranetics Announces First Quarter 2017 Conference Call	GL
23/02/17	Spectranetics Reports Fourth Quarter 2016 Revenue of $71.9 million	GL
06/02/17	Spectranetics : Announces Fourth Quarter 2016 Conference Call	PU
06/02/17	Spectranetics : ILLUMENATE Global 12-month Results Validate Stellarex’s Top-tier Performance in Complex Patient Populations	PU
06/02/17	Spectranetics : Names Scott Hutton as General Manager, Vascular Intervention	PU
02/02/17	Spectranetics Announces Fourth Quarter 2016 Conference Call	GL
24/01/17	ILLUMENATE Global 12-month Results Validate Stellarex’s Top-tier Performance in Complex Patient Populations	GL
11/01/17	Spectranetics Names Scott Hutton as General Manager, Vascular Intervention	GL
28/12/16	Spectranetics to Present at the 35th Annual J.P. Morgan Healthcare Conference	GL
28/12/16	Spectranetics : Research Reports Initiation on Medical Equipment Stocks -- Lantheus, Nevro, Steris, and Spectranetics	PR
21/11/16	Spectranetics Receives CE Mark for Stellarex™ 0.014” Drug-Coated Balloon	GL
21/11/16	Spectranetics : Technical Reports on Medical Equipment Equities -- Lantheus, Nevro, Steris, and Spectranetics	PR